246 related articles for article (PubMed ID: 35693801)
21. A Highly Active Form of XCL1/Lymphotactin Functions as an Effective Adjuvant to Recruit Cross-Presenting Dendritic Cells for Induction of Effector and Memory CD8
Matsuo K; Kitahata K; Kawabata F; Kamei M; Hara Y; Takamura S; Oiso N; Kawada A; Yoshie O; Nakayama T
Front Immunol; 2018; 9():2775. PubMed ID: 30542351
[TBL] [Abstract][Full Text] [Related]
22. Beyond cDC1: Emerging Roles of DC Crosstalk in Cancer Immunity.
Noubade R; Majri-Morrison S; Tarbell KV
Front Immunol; 2019; 10():1014. PubMed ID: 31143179
[TBL] [Abstract][Full Text] [Related]
23. Type I IFN Activating Type I Dendritic Cells for Antitumor Immunity.
Liang Y; Hannan R; Fu YX
Clin Cancer Res; 2021 Jul; 27(14):3818-3824. PubMed ID: 33692027
[TBL] [Abstract][Full Text] [Related]
24. Conventional type 1 dendritic cells (cDC1) in cancer immunity.
Liu P; Zhao L; Kroemer G; Kepp O
Biol Direct; 2023 Nov; 18(1):71. PubMed ID: 37907944
[TBL] [Abstract][Full Text] [Related]
25. Transcription factor Etv6 regulates functional differentiation of cross-presenting classical dendritic cells.
Lau CM; Tiniakou I; Perez OA; Kirkling ME; Yap GS; Hock H; Reizis B
J Exp Med; 2018 Sep; 215(9):2265-2278. PubMed ID: 30087163
[TBL] [Abstract][Full Text] [Related]
26. DNGR-1-mediated cross-presentation of dead cell-associated antigens.
Henry CM; Castellanos CA; Reis e Sousa C
Semin Immunol; 2023 Mar; 66():101726. PubMed ID: 36758378
[TBL] [Abstract][Full Text] [Related]
27. Dendritic cell-targeted therapy expands CD8 T cell responses to bona-fide neoantigens in lung tumors.
López L; Morosi LG; La Terza F; Bourdely P; Rospo G; Amadio R; Piperno GM; Russo V; Volponi C; Vodret S; Joshi S; Giannese F; Lazarevic D; Germano G; Stoitzner P; Bardelli A; Dalod M; Pace L; Caronni N; Guermonprez P; Benvenuti F
Nat Commun; 2024 Mar; 15(1):2280. PubMed ID: 38480738
[TBL] [Abstract][Full Text] [Related]
28. Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141
Masterman KA; Haigh OL; Tullett KM; Leal-Rojas IM; Walpole C; Pearson FE; Cebon J; Schmidt C; O'Brien L; Rosendahl N; Daraj G; Caminschi I; Gschweng EH; Hollis RP; Kohn DB; Lahoud MH; Radford KJ
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32737142
[TBL] [Abstract][Full Text] [Related]
29. Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens.
Jongbloed SL; Kassianos AJ; McDonald KJ; Clark GJ; Ju X; Angel CE; Chen CJ; Dunbar PR; Wadley RB; Jeet V; Vulink AJ; Hart DN; Radford KJ
J Exp Med; 2010 Jun; 207(6):1247-60. PubMed ID: 20479116
[TBL] [Abstract][Full Text] [Related]
30. FLT3-ligand treatment of humanized mice results in the generation of large numbers of CD141+ and CD1c+ dendritic cells in vivo.
Ding Y; Wilkinson A; Idris A; Fancke B; O'Keeffe M; Khalil D; Ju X; Lahoud MH; Caminschi I; Shortman K; Rodwell R; Vuckovic S; Radford KJ
J Immunol; 2014 Feb; 192(4):1982-9. PubMed ID: 24453245
[TBL] [Abstract][Full Text] [Related]
31. Human CD141
Minoda Y; Virshup I; Leal Rojas I; Haigh O; Wong Y; Miles JJ; Wells CA; Radford KJ
Front Immunol; 2017; 8():1419. PubMed ID: 29163495
[TBL] [Abstract][Full Text] [Related]
32. Differential chemokine receptor expression and usage by pre-cDC1 and pre-cDC2.
Cook SJ; Lee Q; Wong AC; Spann BC; Vincent JN; Wong JJ; Schlitzer A; Gorrell MD; Weninger W; Roediger B
Immunol Cell Biol; 2018 Nov; 96(10):1131-1139. PubMed ID: 29920767
[TBL] [Abstract][Full Text] [Related]
33. [Specialized dendritic cells in cross-presentation of exogenous antigens to cytotoxic T lymphocytes].
Alfaro C; Oñate C; Rodríguez A; Pérez-Gracia JL; Fernández de Sanmamed M; Melero I
An Sist Sanit Navar; 2013; 36(3):519-37. PubMed ID: 24406364
[TBL] [Abstract][Full Text] [Related]
34. In Vitro Generation of Murine CD8α
Kirkling ME; Reizis B
Methods Mol Biol; 2023; 2618():109-119. PubMed ID: 36905512
[TBL] [Abstract][Full Text] [Related]
35. Inflammasome activation leads to cDC1-independent cross-priming of CD8 T cells by epithelial cell-derived antigen.
Deets KA; Nichols Doyle R; Rauch I; Vance RE
Elife; 2021 Dec; 10():. PubMed ID: 34939932
[TBL] [Abstract][Full Text] [Related]
36. CD8
Brewitz A; Eickhoff S; Dähling S; Quast T; Bedoui S; Kroczek RA; Kurts C; Garbi N; Barchet W; Iannacone M; Klauschen F; Kolanus W; Kaisho T; Colonna M; Germain RN; Kastenmüller W
Immunity; 2017 Feb; 46(2):205-219. PubMed ID: 28190711
[TBL] [Abstract][Full Text] [Related]
37. Type 1 conventional dendritic cells and interferons are required for spontaneous CD4
Mattiuz R; Brousse C; Ambrosini M; Cancel JC; Bessou G; Mussard J; Sanlaville A; Caux C; Bendriss-Vermare N; Valladeau-Guilemond J; Dalod M; Crozat K
Clin Transl Immunology; 2021; 10(7):e1305. PubMed ID: 34277006
[TBL] [Abstract][Full Text] [Related]
38. Langerin+ CD8alpha+ dendritic cells are critical for cross-priming and IL-12 production in response to systemic antigens.
Farrand KJ; Dickgreber N; Stoitzner P; Ronchese F; Petersen TR; Hermans IF
J Immunol; 2009 Dec; 183(12):7732-42. PubMed ID: 19923446
[TBL] [Abstract][Full Text] [Related]
39. CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells.
del Rio ML; Rodriguez-Barbosa JI; Kremmer E; Förster R
J Immunol; 2007 Jun; 178(11):6861-6. PubMed ID: 17513734
[TBL] [Abstract][Full Text] [Related]
40. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming.
Luri-Rey C; Gomis G; Glez-Vaz J; Manzanal A; Martinez Riaño A; Rodriguez Ruiz ME; Teijeira A; Melero I
Immunol Rev; 2024 Jan; 321(1):143-151. PubMed ID: 37822051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
